549 related articles for article (PubMed ID: 30609134)
1. Long noncoding RNA cancer susceptibility candidate 2 suppresses papillary thyroid carcinoma growth by inactivating the AKT/ERK1/2 signaling pathway.
Huang F; Zhang Q; Chen W; Zhang H; Lu G; Chen J; Qiu C
J Cell Biochem; 2019 Jun; 120(6):10380-10390. PubMed ID: 30609134
[TBL] [Abstract][Full Text] [Related]
2. BRAF-activated LncRNA functions as a tumor suppressor in papillary thyroid cancer.
Liao T; Qu N; Shi RL; Guo K; Ma B; Cao YM; Xiang J; Lu ZW; Zhu YX; Li DS; Ji QH
Oncotarget; 2017 Jan; 8(1):238-247. PubMed ID: 27462868
[TBL] [Abstract][Full Text] [Related]
3. LncRNA CASC2 expression is down- regulated in papillary thyroid cancer and promotes cell invasion by affecting EMT pathway.
Zhou T; Zhong M; Zhang S; Wang Z; Xie R; Xiong C; Lv Y; Chen W; Yu J
Cancer Biomark; 2018; 23(2):185-191. PubMed ID: 30175973
[TBL] [Abstract][Full Text] [Related]
4. BGL3 inhibits papillary thyroid carcinoma progression via regulating PTEN stability.
Zhao M; Yang F; Sang C; Yan C; Wang Z
J Endocrinol Invest; 2021 Oct; 44(10):2165-2174. PubMed ID: 33543443
[TBL] [Abstract][Full Text] [Related]
5. LncRNA HOTTIP promotes papillary thyroid carcinoma cell proliferation, invasion and migration by regulating miR-637.
Yuan Q; Liu Y; Fan Y; Liu Z; Wang X; Jia M; Geng Z; Zhang J; Lu X
Int J Biochem Cell Biol; 2018 May; 98():1-9. PubMed ID: 29474928
[TBL] [Abstract][Full Text] [Related]
6. CRLF1 promotes malignant phenotypes of papillary thyroid carcinoma by activating the MAPK/ERK and PI3K/AKT pathways.
Yu ST; Zhong Q; Chen RH; Han P; Li SB; Zhang H; Yuan L; Xia TL; Zeng MS; Huang XM
Cell Death Dis; 2018 Mar; 9(3):371. PubMed ID: 29515111
[TBL] [Abstract][Full Text] [Related]
7. Long noncoding RNA CASC9 promotes the proliferation and metastasis of papillary thyroid cancer via sponging miR-488-3p.
Chen Y; Li Y; Gao H
Cancer Med; 2020 Mar; 9(5):1830-1841. PubMed ID: 31943867
[TBL] [Abstract][Full Text] [Related]
8. Long non-coding RNA ASMTL-AS1 inhibits tumor growth and glycolysis by regulating the miR-93-3p/miR-660/FOXO1 axis in papillary thyroid carcinoma.
Feng Z; Chen R; Huang N; Luo C
Life Sci; 2020 Mar; 244():117298. PubMed ID: 31953163
[TBL] [Abstract][Full Text] [Related]
9. lncRNA CASC2 Enhances
Tao L; Tian P; Yang L; Guo X
Biomed Res Int; 2020; 2020():7183629. PubMed ID: 33134385
[TBL] [Abstract][Full Text] [Related]
10. A novel lncRNA n384546 promotes thyroid papillary cancer progression and metastasis by acting as a competing endogenous RNA of miR-145-5p to regulate AKT3.
Feng J; Zhou Q; Yi H; Ma S; Li D; Xu Y; Wang J; Yin S
Cell Death Dis; 2019 Jun; 10(6):433. PubMed ID: 31160577
[TBL] [Abstract][Full Text] [Related]
11. Long noncoding RNA SAMMSON promotes papillary thyroid carcinoma progression through p300/Sp1 axis and serves as a novel diagnostic and prognostic biomarker.
Shao L; Sun W; Wang Z; Dong W; Qin Y
IUBMB Life; 2020 Feb; 72(2):237-246. PubMed ID: 31478331
[TBL] [Abstract][Full Text] [Related]
12. LHPP inhibits cell growth and migration and triggers autophagy in papillary thyroid cancer by regulating the AKT/AMPK/mTOR signaling pathway.
Sun W; Qian K; Guo K; Chen L; Xiang J; Li D; Wu Y; Ji Q; Sun T; Wang Z
Acta Biochim Biophys Sin (Shanghai); 2020 Apr; 52(4):382-389. PubMed ID: 32227107
[TBL] [Abstract][Full Text] [Related]
13. MiR-141-3p Suppresses Tumor Growth and Metastasis in Papillary Thyroid Cancer via Targeting Yin Yang 1.
Fang M; Huang W; Wu X; Gao Y; Ou J; Zhang X; Li Y
Anat Rec (Hoboken); 2019 Feb; 302(2):258-268. PubMed ID: 30290400
[TBL] [Abstract][Full Text] [Related]
14. LncRNA PFAR facilitates the proliferation and migration of papillary thyroid carcinoma by competitively binding to miR-15a.
Fang T; Yu K
Naunyn Schmiedebergs Arch Pharmacol; 2024 May; 397(5):3037-3048. PubMed ID: 37874339
[TBL] [Abstract][Full Text] [Related]
15. Long non-coding RNA TTN-AS1 facilitates tumorigenesis of papillary thyroid cancer through modulating the miR-153-3p/ZNRF2 axis.
Cui Z; Luo Z; Lin Z; Shi L; Hong Y; Yan C
J Gene Med; 2019 May; 21(5):e3083. PubMed ID: 30811764
[TBL] [Abstract][Full Text] [Related]
16. STAT3-induced upregulation of lncRNA ABHD11-AS1 promotes tumour progression in papillary thyroid carcinoma by regulating miR-1301-3p/STAT3 axis and PI3K/AKT signalling pathway.
Wen J; Wang H; Dong T; Gan P; Fang H; Wu S; Li J; Zhang Y; Du R; Zhu Q
Cell Prolif; 2019 Mar; 52(2):e12569. PubMed ID: 30657221
[TBL] [Abstract][Full Text] [Related]
17. MicroRNA-31 inhibits papillary thyroid carcinoma cell biological progression by directly targeting SOX11 and regulating epithelial-to-mesenchymal transition, ERK and Akt signaling pathways.
Wang Y; Liu BG; Zhou CX
Eur Rev Med Pharmacol Sci; 2019 Jul; 23(13):5863-5873. PubMed ID: 31298337
[TBL] [Abstract][Full Text] [Related]
18. Long noncoding RNA SNHG22 increases ZEB1 expression via competitive binding with microRNA-429 to promote the malignant development of papillary thyroid cancer.
Gao H; Sun X; Wang H; Zheng Y
Cell Cycle; 2020 May; 19(10):1186-1199. PubMed ID: 32306838
[TBL] [Abstract][Full Text] [Related]
19. Overexpression of cancer susceptibility candidate 2 inhibited progression of hepatocellular carcinoma cells.
Gao X; Du H; Zhang R; Li C; Wang H; Xuan Q; Liu D
J Cell Physiol; 2019 Jun; 234(6):9008-9018. PubMed ID: 30362539
[TBL] [Abstract][Full Text] [Related]
20. MicroRNA‑766 inhibits papillary thyroid cancer progression by directly targeting insulin receptor substrate 2 and regulating the PI3K/Akt pathway.
Zhao J; Li Z; Chen Y; Zhang S; Guo L; Gao B; Jiang Y; Tian W; Hao S; Zhang X
Int J Oncol; 2019 Jan; 54(1):315-325. PubMed ID: 30387841
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
